Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Joy C. Yang(University of California, Davis), Chengfei Liu(University of California, Davis)
Cited by 18
Related Papers
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
|Journal for ImmunoTherapy of Cancer|2023|64
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
|Pharmacological Research|2023|20
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer
|Nature Communications|2024|6